药品不良反应的手性因素

中国药物警戒 ›› 2013, Vol. 10 ›› Issue (10): 616-619.

药品不良反应的手性因素

宋海波,杨乐,郭晓昕,杜晓曦^*

国家食品药品监督管理总局药品评价中心,北京 100045

收稿日期:2013-06-03 修回日期:2016-03-09 出版日期:2013-10-08 发布日期:2016-03-09
通讯作者: 杜晓曦,女,主任药师,药品技术评价与药品风险管理。 E-mail:duxiaoxi@cdr.gov.cn
作者简介:宋海波,男,博士,副主任药师,临床药理研究。

The Chiral Factor of Aadverse Drug Reaction

SONG Hai -bo ,YANG Le ,GUO Xiao -xin ,DU Xiao –xi

Center for Drug Reevaluation, CFDA,Beijing 100045, China

Received:2013-06-03 Revised:2016-03-09 Online:2013-10-08 Published:2016-03-09

摘要/Abstract

摘要： 综述了国内外有关手性药物的研究进展,归纳了手性药物消旋体及单一对映体间药效学及药动学差异可能导致的不良反应风险因素,介绍了手性药物安全性的研究方法。加强对手性药物的研究,对预防控制其不良反应十分必要。

关键词: 不良反应, 手性药品, 药理活性, 药动学

Abstract: This paper gives an overview about the current status of domestic and foreign research progress of chiral drugs, summarizes the risk factors of adverse reactions induced by the pharmacodynamics and pharmacokinetic differences between racemates and enantiomers, describes the research Methods of chiral drug safety. To prevent and control the adverse reactions of chiral drugs, it is essential to strengthen the research.

Key words: adverse reactions, chiral drugs, pharmacological activity, pharmacokinetics

中图分类号:

R994.11

宋海波,杨乐,郭晓昕,杜晓曦 . 药品不良反应的手性因素[J]. 中国药物警戒, 2013, 10(10): 616-619.

SONG Hai -bo ,YANG Le ,GUO Xiao -xin ,DU Xiao –xi. The Chiral Factor of Aadverse Drug Reaction [J]. Chinese Journal of Pharmacovigilance, 2013, 10(10): 616-619.

参考文献

[1] Rentsch K M. The importance of stereoselective determination of drugs in the clinical laboratory[J].J BiochemBiophysMethods,2002,54(1): 1-9.
[2] Castoldi D, Oggioni A, Renoldi M I, et al. Assay of moguisteine metabolites in human plasma and urine: conventional and chiralhigh-performance liquid chromatographicmethods[J].J Chromatogr B Biomed Appl,1994,655(2): 243-252.
[3] Oti-Amoako K, Vozeh S, Ha HR, et al. The relative potency of major metabolitesandenantiomersof propafenoneinan experimental reperfusion arrhythmia model[J].J Cardiovasc Pharmacol,1990,15(1):75-81.
[4] GurjarMK. The future lies in chiral purity: a perspective[J]. J Indian Med Assoc,2007,105(4): 177-178.
[5] DingYS, Fowler J S, VolkowND,et al. Chiral drugs: comparison of thepharmacokinetics of [11C]d-threoandL-threo-methylphenidate in the human and baboon brain[J].Psychopharmacology(Berl),1997,131(1): 71-78.
[6] Smith S W. Chiral toxicology: it's the same thing. only different[J].Toxicol Sci,2009,110(1): 4-30.
[7] Svensson S, Mansfield P R. Escitalopram: superior to citalopram or a chiral chimera[J]. Psychother Psychosom,2004,73(1):10-16.
[8] Zhang J, Zhou F, Niu F ,et al. Stereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics[J]. PLoS One, 2012,7(4): e35768.
[9] Reddy I K, Kommuru T R, Zaghloul A A, et al. Chirality and its implications in transdermal drug development [J]. Crit Rev Ther Drug Carrier Syst,2000,17(4):285-325.
[10] Cizmarikova R, Valentova J, Hutta J A. [Adrenergic beta-receptor blockers-a group of chiral drugs: enantioseparation in the group of beta-blockers][J]. Ceska Slov Farm,2004,53(1): 9-17.
[11] May T W, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine[J]. Clin Pharmacokinet,2003,42(12): 1023-1042.
[12] Caraballo I. Factors affecting drug release from hydroxypropyl methylcellulose matrix systems in the light of classical and percolationtheories[J].Expert OpinDrugDeliv,2010,7(11): 1291-1301.
[13] Walle U K, Fagan T C, Topmiller M J, et al. The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomers[J]. Br J Clin Pharmacol,1994,37(1): 21-25.
[14] Hatami M, Farhadi K, Tukmechi A. Fiber-based liquid-phase micro-extraction of mebeverine enantiomers followed by chiral high-performance liquid chromatographyanalysis and its application to pharmacokinetics study in rat plasma[J]. Chirality,2012,24(8):634-639.
[15] Kwok D W, Kerr C R, McErlane K M. Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell
distribution of the enantiomers[J].Xenobiotica,1995,25(10): 1127-1142.
[16] Wu Z, Upadhyaya P, Carmella S G, et al. Disposition of 4-（methylnitrosamino）-1-（3-pyridyl）-1-butanone（NNK）and 4-（methylnitrosamino）-1-（3-pyridyl）-1-butanol（NNAL）in bile
duct-cannulated rats:stereoselective metabolism and tissue distribution[J]. Carcinogenesis,2002,23(1): 171-179.
[17] Eyles D W, McGrath J J, Stedman T J, et al. Chirality of reduced haloperidol in humans[J]. Eur Neuropsychopharmacol,1998,8(2):127-129.
[18] Nandi V, Soine W H. HPLC analysis for amobarbital N-glycosides in urine[J]. J Pharm Biomed Anal,1997,15(8): 1187-1195.
[19] Wu M, Zhou X J, Konno R, et al. D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminase[J].ClinExpPharmacolPhysiol,2006,33(11):1042-1046.
[20] Zhao M, Li LP, Sun DL ,et al. Stereoselective metabolism of tetrahydropalmatine enantiomers in rat liver microsomes [J] .Chirality,2012,24(5): 368-373.
[21] AmesMM, Frank S K. Stereochemical aspects of para-chloroamphetamine metabolism. Rabbit liver microsomal metabolism of RS-, R（-）-. and S（+）-para-chloroamphetamine [J]. Biochem
Pharmacol,1982,31(1): 5-9.
[22] Kirchheiner J, Ufer M, Walter E C ,et al. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers[J]. Pharmacogenetics,2004,14(1): 19-26.
[23] Foster R T, Jamali F, Russell A S, et al. Pharmacokinetics of ketoprofenenantiomers in young and elderlyarthritic patients followingsingle andmultiple doses[J].J PharmSci,1988,77(3): 191-195.
[24] Brocks D R, Mehvar R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of he chiral antimalarial drugs[J]. Clin Pharmacokinet,2003,42(15): 1359-1382.
[25] Wang L,McNamara P J. Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk[J]. Drug Metab Dispos,2012,40(5): 1018-1023.